In Brief: House oversight hearing
This article was originally published in The Gray Sheet
Executive SummaryHouse oversight hearing: Rep. Joe Barton's (R-Tex.) House Commerce/Oversight Subcommittee will hold a hearing May 25 on drugs and biologics. Three panels are expected to testify, including: individuals who claim to have suffered as a result of FDA regulation; physicians who say they need certain pharmaceuticals but are unable to obtain them; and outside interest groups. The agency will not be asked to testify. A similar hearing focusing on FDA regulation of medical devices was held March 30 ("The Gray Sheet" April 3, p. 8). The subcommittee is said to be planning two additional hearings for this summer, with one focusing on think-tank proposals for FDA reform and the other on FDA's views...
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.